Cardiff Oncology公司公布的最新临床数据显示,其30毫克剂量Onvansertib联合FOLFIRI化疗方案与贝伐珠单抗的治疗组,取得了高达72.2%的客观缓解率。这一结果与标准治疗组42.1%的客观缓解率形成了鲜明对比,展现出显著的疗效优势。
Cardiff Oncology公司公布的最新临床数据显示,其30毫克剂量Onvansertib联合FOLFIRI化疗方案与贝伐珠单抗的治疗组,取得了高达72.2%的客观缓解率。这一结果与标准治疗组42.1%的客观缓解率形成了鲜明对比,展现出显著的疗效优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.